Meridian Bioscience Announces European Launch of New Rapid Test for Severe Colitis
CINCINNATI--(BUSINESS WIRE)--May 17, 2004--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it has begun to sell its newest product, ImmunoCard Toxins A&B in the European market. This important new test detects toxins produced by strains of the Clostridium difficile bacterium (C. difficile). C. difficile is recognized as the major causative agent of colitis (inflammation of the colon) and diarrhea that may occur following antibiotic therapy. In hospitals or nursing home facilities where C. difficile is prevalent and patients frequently receive antibiotics, the disease is very common. ImmunoCard Toxins A&B is a simple, rapid test that provides clear cut, color-change results in minutes.
Antonio Interno, President and Managing Director Meridian Bioscience Europe, stated, "C. difficile infection represents one of the most common hospital infections around the world. We have begun distributing our ImmunoCard Toxins A&B test to all European markets and we are encouraged by the positive feedback from our customers."
Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral, urinary and respiratory infections. All Meridian diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents and specialty biologicals along with proteins and other biologicals used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices and diagnostics manufacturers in more than 60 countries around the world. The Company's shares are traded through Nasdaq's National Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.
CONTACT: Meridian Bioscience, Inc.
John A. Kraeutler, 513-271-3700
SOURCE: Meridian Bioscience, Inc.